The Food and Drug Administration, FDA for short, is the US federal agency for the regulation of numerous public health and consumer protection products. For medicinal products, it evaluates applications prior to marketing and monitors products after approval. Its decisions apply to the US market and are not to be equated with a European centralized marketing authorization.
Mandate and responsibilities of the FDA
The FDA protects public health by monitoring, among other things, the safety and efficacy of human and veterinary drugs, biological products, and medical devices. Its scope of responsibility also includes food, cosmetics, tobacco products, and radiation-emitting products. In the pharmaceutical sector, its activities include accompanying development, reviewing marketing applications, inspections, and monitoring quality and safety after market entry. Its oversight thus extends over the entire life cycle of regulated products and includes post-market controls.
For clinical development, the FDA is particularly relevant via the framework of the Federal Food, Drug, and Cosmetic Act and the associated regulations in Title 21 of the Code of Federal Regulations. An investigational program must provide data that enable a benefit-risk assessment, manufacturing quality, and appropriate labeling. Depending on the product and legal basis, the agency decides on the acceptance and evaluation of applications; a positive scientific discussion does not replace a formal approval decision.
CDER and CBER
Within the FDA, the Center for Drug Evaluation and Research, CDER, is responsible for prescription and over-the-counter drugs, generics, biosimilars, and numerous therapeutic biological products. CDER evaluates scientific and regulatory data to assess safety, quality, and efficacy. For a new drug, the New Drug Application is a central application type; abbreviated applications and other procedures follow their respective statutory requirements.
The Center for Biologics Evaluation and Research, CBER, regulates biological products for human use under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. These include, for example, certain blood products, vaccines, and other CBER-assigned biologics. Responsibility is not determined solely by the colloquial term “biologic”: therapeutic biological products can be assigned to CDER or CBER depending on their product class. For biological products, the Biologics License Application is a key approval pathway.
Distinction from the EMA and the European approval model
The FDA and the European Medicines Agency, EMA, fulfill different institutional roles. The FDA is a US federal agency that makes regulatory decisions for the American market within its statutory jurisdiction. The EMA is an agency of the European Union. In the centralized European procedure, its Committee for Medicinal Products for Human Use issues a scientific opinion, while the European Commission grants the legally binding marketing authorization.
In addition to the centralized procedure, Europe has national, decentralized, and mutual recognition procedures. The FDA does not grant European authorization, and the EMA does not itself grant centralized EU authorization. Similar terms must also not be equated across legal systems: a US NDA, a Biologics License Application, and a European Marketing Authorisation Application follow different legal bases, responsibilities, and procedural steps. Scientific advice, dossier evaluation, and legally binding authorization are institutionally separate steps in the European model.
Relevance for clinical trials
For clinical trials relating to a subsequent US submission, the protocol, data collection, safety monitoring, and documentation of trial results must be aligned with the requirements of the intended application. Of practical relevance are clear responsibilities between the sponsor, investigator sites, and service providers, robust quality processes, and the early classification of whether a product is managed by CDER or CBER. Inspections and the evaluation of the integrity of clinical data can affect the traceability of the entire development program.
Full-service CROs such as Mediconomics support regulatory strategy, the preparation and management of clinical trials, site management, monitoring, data management, pharmacovigilance, biostatistics, and medical writing. For FDA-related projects, this also includes structuring data, clinical study reports, and safety information so that they are consistently and traceably available for a later NDA or BLA.
Frequently Asked Questions (FAQ)
Is the FDA responsible for all health products in the US?
The FDA has a broad scope of responsibility for medicinal products, biological products, medical devices, and other product groups. However, specific responsibility depends on the type of product and statutory requirements.
What is the difference between CDER and CBER?
CDER oversees medicinal products including many therapeutic biologics, while CBER is responsible for certain biological products. The assignment follows the product class and cannot be derived from the designation alone.
Does the EMA grant EU marketing authorization?
In the centralized procedure, the EMA carries out the scientific evaluation. The legally binding marketing authorization is granted by the European Commission.
Regulatory references
- Federal Food, Drug, and Cosmetic Act — central US legal basis for medicinal products and applications.
- Public Health Service Act, Section 351 — basis for the licensing of biological products.
- 21 CFR Part 314 — regulations on applications for marketing a new drug.
- Regulation (EC) No 726/2004 — regulates the centralized EU procedure and the role of the EMA.